HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

• Published in: Journal of the American College of Cardiology Vol. 30; no. 5; pp. 1212 - 1217
• Main Authors: Weber, Christian, Erl, Wolfgang, Weber, Kim S.C, Weber, Peter C
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.1997
• Subjects: Cell Adhesion - drug effects; Cells, Cultured; Endothelium, Vascular - cytology; Endothelium, Vascular - drug effects; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; Lovastatin - pharmacology; Lovastatin - therapeutic use; Macrophage-1 Antigen - metabolism; Male; Monocytes - drug effects; Monocytes - metabolism; Simvastatin - pharmacology; Simvastatin - therapeutic use; HDL; GTP; MCP-1; LDL; HMG-CoA; ICAM-1; PBMCs; CHD; HUVECs; mAb

Objectives. This study sought to determine whether inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase affect CD11b expression and adhesiveness of monocytes in vitro and after treatment of patients with hypercholesterolemia. Background. HMG-CoA reductase inhibitors improve survi...